Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Gaynor JJ and Ciancio G | The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. | 2018 | Transplantation | pmid:29271869 |
Cavaillé-Coll MW and Elashoff MR | Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. | 1998 | Transplantation | pmid:9448161 |
Silva HT et al. | Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. | 2014 | Transplantation | pmid:24521771 |
Faguer S et al. | Rituximab therapy for acute humoral rejection after kidney transplantation. | 2007 | Transplantation | pmid:17496547 |
Heffron TG et al. | Pediatric liver transplantation with daclizumab induction. | 2003 | Transplantation | pmid:12829908 |
Gonwa TA et al. | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | 2001 | Transplantation | pmid:11773892 |
Fisher RA et al. | A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9884248 |
Aulagnon F et al. | Diarrhea after kidney transplantation: a new look at a frequent symptom. | 2014 | Transplantation | pmid:25073040 |
Gallon L et al. | ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. | 2006 | Transplantation | pmid:16477235 |
Neumann UP et al. | Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. | 2001 | Transplantation | pmid:11374419 |
Andries S et al. | Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. | 2001 | Transplantation | pmid:11477351 |
Riegersperger M et al. | Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. | 2013 | Transplantation | pmid:23594858 |
Josephson MA et al. | Treatment of renal allograft polyoma BK virus infection with leflunomide. | 2006 | Transplantation | pmid:16534472 |
Taler SJ et al. | Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. | 1996 | Transplantation | pmid:8970613 |
Buell JF et al. | Malignancy after transplantation. | 2005 | Transplantation | pmid:16251858 |
Gouraud A et al. | Follow-up of tacrolimus breastfed babies. | 2012 | Transplantation | pmid:22996303 |
Blakolmer K et al. | Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. | 2000 | Transplantation | pmid:10868635 |
Miller J et al. | Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. | 2000 | Transplantation | pmid:10755543 |
Inamura N et al. | Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. | 1988 | Transplantation | pmid:2447690 |
MacPhee IA and Holt DW | A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. | 2008 | Transplantation | pmid:18212618 |